Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Condition(s):Soft Tissue SarcomaLast Updated:January 3, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):Soft Tissue SarcomaLast Updated:January 3, 2019Unknown status
Condition(s):Hepatocellular CancerLast Updated:July 12, 2022Recruiting
Condition(s):Relapsed Small Cell Lung Cancer; AnlotinibLast Updated:February 17, 2021Recruiting
Condition(s):Soft Tissue Sarcoma; High Risk of Recurrence; Anlotinib; RadiotherapyLast Updated:November 2, 2022Recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:February 1, 2022Not yet recruiting
Condition(s):Anlotinib; Anti-PD-1 Antibody; Advanced Pancreatic CancerLast Updated:June 22, 2023Recruiting
Condition(s):Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorLast Updated:October 26, 2023Recruiting
Condition(s):Endometrial Cancer; Ovarian Cancer; Cervical CancerLast Updated:June 19, 2019Terminated
Condition(s):Gastric Cancer; Adenocarcinoma of Esophagogastric JunctionLast Updated:May 19, 2021Unknown status
Condition(s):Non Small Cell Lung CancerLast Updated:November 26, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.